July 29, 2009
Kevin E. Lofton Joins Gilead Sciences' Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 29, 2009--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Kevin E.
Lofton has been appointed to the company’s Board of Directors, bringing
the number of Directors to 12.
Mr. Lofton is currently the President and Chief Executive Officer of
Catholic Health Initiatives, a Denver-based healthcare system operating
the full continuum of services from hospitals to home health agencies
throughout the nation. He previously served as Chief Executive Officer
of two university hospitals, the University of Alabama at Birmingham
Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr.
Lofton served as Chairman of the Board of the American Hospital
Association, the nation’s largest hospital trade association. Mr. Lofton
currently serves on the Board of Directors of the Morehouse School of
Medicine, Atlanta, and the Georgia State University J. Mack Robinson
College of Business, also in Atlanta.
“We are very pleased to welcome Kevin Lofton to Gilead’s Board of
Directors,” said John Martin, PhD, Chairman and Chief Executive Officer,
Gilead Sciences. “In Kevin’s many years leading hospital and healthcare
systems, he has demonstrated a commitment to ensuring that patients have
access to medical services. His broad expertise and knowledge in real
world hospital administration and patient care will be invaluable in
helping Gilead to deliver innovative therapeutics to individuals with
life-threatening diseases.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit the company's
website at www.gilead.com
or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy
Flood, 650-522-5643 (Media)
